Study of Lanadelumab for Long-term Prevention of Acquired Angioedema Attacks

What this Trial Is About

Researchers are evaluating the use of lanadelumab for long-term prevention of attacks in patients with acquired angioedema AAE. This phase 4 study focuses on patients who experience recurrent angioedema attacks without urticaria and have specific blood markers such as decreased C1 inhibitor levels and presence of anti-C1INH antibody or paraproteinemia. The goal is to assess lanadelumabs role in reducing attack frequency over time. All participants in the study will receive open-label lanadelumab at a dose of 300 mg. This means everyone enrolled will be treated with lanadelumab without a comparison group or placebo. The treatment is administered to evaluate its effect on attack prevention in this patient population. During the study, participants will be monitored for at least 12 months to observe the primary outcome related to attack frequency and treatment impact. Researchers will collect data on attacks and overall health status to assess the long-term effects of lanadelumab. Participants will have regular study visits and assessments to track their condition and treatment response.

Lanadelumab in Long-term Prophylaxis of Acquired Angioedema